Dated: October 30, 1997.

Joanne Lanahan,

Director, Health Care Administrative Sanctions, Office of Investigations, OI.

[FR Doc. 97–29792 Filed 11–12–97; 8:45 am]

BILLING CODE 4150–04–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment Request; 'Test-Retest Study of the Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS–IV) in a General Population Sample'

SUMMARY: In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, which provides for an opportunity for public comment on proposed data collection projects, the National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Proposed Collection

The Biometry Branch (BB), Division of Biometry and Epidemiology (DBE), NIAAA, intends to conduct the 'Test-Retest Study of the Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS–IV) in a General Population Sample' to assess the test-retest reliability of new sections of the AUDADIS–IV in a general population sample. The AUDADIS–IV is a fully-structured interview designed to collect information on alcohol and drug use disorders and their associated psychiatric and medical conditions. The NIAAA is authorized by Section 464H of Title IV of the Public Health Act (42 U.S.C. 285n).

The information proposed for collection in this study will be used by the NIAAA to develop and finalize psychometrically sound measures of alcohol and drug-related disabilities for use in major epidemiologic surveys conducted in the United States. Currently, there is a great need for more reliable measurement of alcohol and drug use disorders and their associated disabilities in all fields of substance use research.

The annual burden estimates are as follows:

Type and number of respondents	Responses per respondent	Total responses	Hours	Total hours
(First (Test Interviews) 500	1	500	1	500
(Second (Retest) Interviews) 500	1	500	1	500
Total Number of Respondents—500 (per year)				
Total Number of Responses—1000 (per year)				
Total hours—1000 (per year)				

Request for Comments

Comments are invited on: (a) Whether the proposed collection is necessary, including whether the information has practical use; (b) ways to enhance the clarity, quality, and use of the information to be collected; (c) the accuracy of the agency estimate of burden of the proposed collection; and (d) ways to minimize the collection burden of the respondents. Send written comments to Dr. Bridget Grant, Biometry Branch, Division of Biometry and Epidemiology (DBE), NIAAA, NIH, Willco Bldg., Suite 514, 6000 Executive Boulevard, Bethesda, Maryland 20892–7003.

For Further Information

To request more information on the proposed project or to obtain a copy of the data collection plans, contact Dr. Bridget Grant, Biometry Branch, Division of Biometry and Epidemiology, NIAAA, Willco Bldg., 6000 Executive Boulevard, Suite 514, Bethesda, Maryland 20892–7003, or call non-toll-free number (301) 443–7370.

Comments Due Date

Comments regarding this information collection are best assured of having their full effect if received on or before January 12, 1998.

Dated: November 5, 1997.

Martin K. Trusty,

Executive Officer, NIAAA.

[FR Doc. 97–29841 Filed 11–12–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Identification of the Gene Causing Familial Mediterranean Fever

D Kastner (NIAMS) et al.
Serial No. 60/056,217 filed 21 Aug. 97
Licensing Contact: Stephen Finley, 301/496–7056 ext. 215

The invention identifies the gene (MEFV) encoding the protein (pyrin) that is associated with familial Mediterranean fever (FMF). FMF, a recessive inherited disorder, is characterized by episodes of fever, inflammation, and unexplained arthritis, pleurisy, or abdominal pain. Pyrin is thought to play a role in keeping inflammation under control, whereas mutated forms lead to a malfunctioning protein and uncontrolled inflammation. Mutated forms of MEFV were isolated and correlated to FMF disease. It is anticipated that the immediate use of the pyrin gene and its mutations will be to aid in the diagnosis of FMF. It may also prove useful for evaluating FMF as a possible cause of currently unexplained fevers or abdominal pain.

The normal gene and its mutations may also be useful for studying and controlling inflammation.

Methods for Inactivating Enveloped RNA Virus Particles and Compositions for Use Therewith

HF Rosenberg, JB Domachowske (NIAID)
Serial Number: 60/052,986 filed 02 Jul 97
Licensing Contact: Robert Benson, 301/496–7056 ext. 267

The inventors have discovered that treatment of enveloped single-stranded RNA viruses with eosinophil-derived neurotoxin (EDN), a ribonuclease, inactivates the viruses in cell culture. Respiratory Syncytial Virus (RSV) and Parainfluenza Virus (PIV) are medically the most important enveloped RNA viruses; together they hospitalize over 100,000 infants per year in the US. EDN is the major eosinophil ribonuclease. It has been cloned and recombinant EDN is available. Despite its name, EDN is not toxic to respiratory epithelial or other somatic cells. Both parenteral and aerosol administration are contemplated. Claimed are methods of treatment and pharmaceutical compositions.

Actinomycin D: A New Use for AIDS Therapy

JG Levin, J Guo (NICHD)
Serial No. 60/047,223 filed 20 May 97
Licensing Contact: Robert Benson, 301/496–7056 ext. 267

This invention is a method of treating HIV infection by administering Actinomycin D. In a broader sense the invention is the discovery of a new target for anti-HIV therapy, namely the inhibition of the first strand transfer step in reverse transcription, an early step in HIV replication. Actinomycin D, a licensed drug used to treat Wilm's tumor, inhibits the first strand transfer step at a concentration estimated to be an order of magnitude lower than that used to treat cancer, as shown by inhibition studies with purified reverse transcriptase and detergent-treated HIV virions.

Rapid Method for Diagnosing the Various Forms of Alpha-Thalassemia

GP Rodgers, DC Tang (NIDDK)
Serial No. 60/031,880 filed 27 Nov 96
Licensing Contact: J. Peter Kim, 301/496–7056 ext. 264

The present invention is directed to a simple, inexpensive, and rapid method for detecting thalassemias. The present invention provides for the identification of nucleic acid primers capable of detecting and distinguishing between the various forms of alpha-thalassemia using any biological material (dry or fluid) containing nucleic acid material. The invention further provides for a method and diagnostic kit for the detection and quantitation of hemoglobin (Hb) alpha gene(s) in alpha-thalassemia patients, a method and kit for screening for carriers of this genetic disorder, a sensitive non-radioisotopic test capable of differentiating between the various forms of thalassemia, and a means to identify persons who are at risk of having offspring with homozygous alpha-thalassemia.

Dated: November 4, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97–29843 Filed 11–12–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Meeting of the National Advisory Board on Medical Rehabilitation Research

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the National Advisory Board on Medical Rehabilitation Research, National Institute of Child Health and Human Development, November 24–25, 1997, Natcher Conference Center, Conference Rooms E1–E2, Bethesda, Maryland.

The meeting will be open to the public from 8:00 a.m. to 5:00 p.m. on November 24 and 8:00 a.m. to adjournment on November 25. Attendance by the public will be limited to space available. Board topics will include: (1) A report on fiscal issues concerning the National Center for Medical Rehabilitation Research (Center) and the Institute; (2) reports on the program activities of the Center; (3) a discussion of general priority areas of research for the Center; and (4) a discussion of support for medical rehabilitation research by government agencies.

Ms. Debbie Welty, Board Secretary, NICHD, 6100 Building, Room 2A03, National Institutes of Health, Bethesda, Maryland 20892, Area Code 301–402–2242, will provide a summary of the meeting and a roster of Advisory Board members as well as substantive program information. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Welty.

Dated: November 6, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–29847 Filed 11–12–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Cancer Drug Discovery: Diversity Generation and Smart Assays.

Date: December 14–16, 1997.

Time: December 14–7:00 p.m. to Recess, December 15–8:00 a.m. to Recess, December 16–8:00 a.m. to Adjournment.

Place: Key Bridge Marriott, 1401 Lee Highway, Arlington, VA 22209.

Contact Person: Ray Bramhall, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 643, 6130 Executive Boulevard, MSC 7407, Bethesda, MD 20892–7407, Telephone: 301/496–3428.

Purpose/Agenda: To review, discuss and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: November 6, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–29844 Filed 11–12–97; 8:45 am]

BILLING CODE 4140–01–M